🔎 Trials Near Me

Utama › Kanser Paru-paru › Utah › Salt Lake City

Kajian klinikal Kanser Paru-paru di Salt Lake City, UT

21 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Salt Lake City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Mengambil pesertaFasa 3
  • Utah Cancer Specialists, Salt Lake City
  • Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06881784

SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • University of Utah, Salt Lake City
  • Veterans Affairs SLC Health Care System (VAMC), Salt Lake City
Umur 21 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07460440

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Mengambil pesertaFasa 2/3
  • Utah Cancer Specialists, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06712316

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Mengambil pesertaFasa 1
  • Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06343402

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Mengambil pesertaFasa 3
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT06500481

Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics

Mengambil pesertaSukarelawan sihat dialu-alukan
  • Huntsman Cancer Institute/ University of Utah, Salt Lake City
Umur 50 hingga 80 · Semua jantina · Dikemas kini 21 Jul 2026 · NCT07716280

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Mengambil pesertaFasa 1
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07458347

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05642572

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Mengambil pesertaFasa 1/2
  • Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Mengambil pesertaFasa 1/2
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Mei 2026 · NCT06922591

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2/3
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • Huntsman Cancer Institute/University of Utah, Salt Lake City
18 Minutes · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06031688

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Mengambil peserta
  • George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT05297734

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Mengambil pesertaFasa 1/2
  • Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT07020221

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Mengambil pesertaFasa 1/2
  • University of Utah, Huntsman Cancer Institute, Salt Lake City
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT06810544

Improving Care for Rural Patients With Solid Tumors

Mengambil peserta
  • Huntsman Cancer Institute at the University of Utah, Salt Lake City
Umur 18 hingga 99 · Semua jantina · Dikemas kini 5 Feb 2026 · NCT04916990

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Mengambil pesertaFasa 1/2
  • Utah Cancer Specialists (site 203), Salt Lake City
Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Dis 2025 · NCT03556228

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Salt Lake City
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Kajian Kanser Paru-paru di bandar lain

Kajian lain di Salt Lake City

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.